BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15770529)

  • 21. Allelic loss on a chromosome 17 in ductal carcinoma in situ of the breast.
    Radford DM; Fair K; Thompson AM; Ritter JH; Holt M; Steinbrueck T; Wallace M; Wells SA; Donis-Keller HR
    Cancer Res; 1993 Jul; 53(13):2947-9. PubMed ID: 8391383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.
    Tse GM; Tan PH; Moriya T
    J Clin Pathol; 2009 May; 62(5):407-13. PubMed ID: 19126567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas.
    Mueller J; Gansauge S; Mattfeldt T
    Hepatogastroenterology; 2003; 50(50):541-4. PubMed ID: 12749268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clonal origin of lymph node metastases in bladder carcinoma.
    Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
    Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A region close to Tp53 shows LOH in familial breast cancer.
    Luo L; Chen J; Du Q; Dumanski J; Blennow E; Kockum I; Luthman H; Lindblom A
    Int J Mol Med; 2002 Apr; 9(4):405-9. PubMed ID: 11891537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of heterozygosity in ductal lavage for breast tumor and the contralateral breast.
    Yonekura Y; Yamamoto D; Okugawa H; Tanaka K; Kamiyama Y
    Oncol Rep; 2005 Apr; 13(4):739-43. PubMed ID: 15756451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the progression of intraductal proliferative lesions in the breast by PCR-based clonal assay.
    Yu Q; Niu Y; Yu Y; Ding X; Shi Y
    Breast Cancer Res Treat; 2009 Apr; 114(3):433-40. PubMed ID: 18425676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of multiple breast cancers of multicentric origin by histological observations and distribution of allele loss on chromosome 16q.
    Tsuda H; Hirohashi S
    Cancer Res; 1995 Aug; 55(15):3395-8. PubMed ID: 7614478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model.
    Worsham MJ; Pals G; Schouten JP; Miller F; Tiwari N; van Spaendonk R; Wolman SR
    Breast Cancer Res Treat; 2006 Mar; 96(2):177-86. PubMed ID: 16319984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.
    Hartmann A; Schlake G; Zaak D; Hungerhuber E; Hofstetter A; Hofstaedter F; Knuechel R
    Cancer Res; 2002 Feb; 62(3):809-18. PubMed ID: 11830537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genome-wide allelotyping of a new in vitro model system reveals early events in breast cancer progression.
    Li Z; Meng ZH; Sayeed A; Shalaby R; Ljung BM; Dairkee SH
    Cancer Res; 2002 Oct; 62(20):5980-7. PubMed ID: 12384566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors.
    Larson PS; de las Morenas A; Cerda SR; Bennett SR; Cupples LA; Rosenberg CL
    J Pathol; 2006 Jul; 209(3):307-16. PubMed ID: 16604511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas.
    McCarthy RP; Wang M; Jones TD; Strate RW; Cheng L
    Clin Cancer Res; 2006 Apr; 12(8):2414-8. PubMed ID: 16638846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
    Keohavong P; Gao WM; Mady HH; Kanbour-Shakir A; Melhem MF
    Cancer Lett; 2004 Aug; 212(1):121-30. PubMed ID: 15246568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of heterozygosity, microsatellite instability and TP53 gene status in ovarian carcinomas.
    Plisiecka-Hałasa J; Dansonka-Mieszkowska A; Kraszewska E; Dańska-Bidzińska A; Kupryjańczyk J
    Anticancer Res; 2008; 28(2A):989-96. PubMed ID: 18507046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type.
    Vos CB; ter Haar NT; Rosenberg C; Peterse JL; Cleton-Jansen AM; Cornelisse CJ; van de Vijver MJ
    Br J Cancer; 1999 Dec; 81(8):1410-8. PubMed ID: 10604741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Molecular changes in development and progression of urothelial carcinoma].
    Hartmann A
    Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of heterozygosity and allelic imbalance in apocrine metaplasia of the breast: microdissection microsatellite analysis.
    Selim AG; Ryan A; El-Ayat G; Wells CA
    J Pathol; 2002 Mar; 196(3):287-91. PubMed ID: 11857491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clonal analysis of predominantly intraductal carcinoma and precancerous lesions of the breast by means of polymerase chain reaction.
    Noguchi S; Motomura K; Inaji H; Imaoka S; Koyama H
    Cancer Res; 1994 Apr; 54(7):1849-53. PubMed ID: 7907946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
    Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
    Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.